Eli Lilly’s Oral GLP-1 Foundation Trails Novo Nordisk’s Wegovy Pill in Early Obesity Launch Uptake, According to Spherix Global Insights
Despite a more flexible administration profile, Foundayo generated lower first-month prescribing rates than the Wegovy Pill among both primary care physicians (PCPs) and endocrinologists. EXTON, PA, May 27, 2026 — As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients hesitant to initiate injectable weight […]
Spherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment
High adoption rates for obesity treatment are noted across both LillyDirect and NovoCare platforms, but key workflow differences drive a split in preferences EXTON, PA, April 24, 2026 — As the obesity treatment landscape evolves, new access channels are reshaping how patients receive care. Since the launch of Eli Lilly’s LillyDirect in January 2024 and […]
Novo’s oral semaglutide edges out CagriSema, Lilly’s orforglipron as PCPs’ most-anticipated obesity med
Oral semaglutide, which Novo has taken to calling “Wegovy in a pill,” is expected to receive an FDA decision before the end of the year. As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights surveyed […]
Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights
US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness. Exton, PA., December 9, 2025 – Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape. In November, the FDA granted National Priority Vouchers, and thus expedited […]
Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk’s Wegovy in MASH, According to Spherix Global Insights
US Gastroenterologists and hepatologists highlight strong interest in Wegovy for addressing the metabolic roots of MASH. Exton, PA, August 28, 2025 – The recent approval of Novo Nordisk’s Wegovy (semaglutide 2.4mg) as the second treatment for metabolic dysfunction-associated steatohepatitis (MASH) represents a critical step forward in a condition with a vast patient population and significant […]
Patient-Led Decisions Accelerate IBD Treatment Switching, Spherix Global Insights Finds
New patient chart audit uncovers rising wave of patient-driven treatment switches in ulcerative colitis and Crohn’s disease, opening the door for brands to accelerate market share gains. Exton, PA, August 26, 2025 – Patients with inflammatory bowel disease (IBD) in the US are taking a more active role than ever before in the decision to […]
Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi
Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights. Exton, PA, August 6, 2025 – The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK inhibitors, continue displace […]
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Despite new market entrants in the form of Gilead’s Livdelzi and Ipsen’s Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need. Exton, PA, July 17, 2025 – The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, […]
Timely Findings Highlight Increased US Physician Familiarity with IRA Changes Amid Ongoing Reimbursement and Education Concerns, According to Spherix Global Insights
Recently released research reveals key insights into physician perspectives, practice management changes, and expected prescribing changes resulting from recent IRA-driven Medicare changes. EXTON, PA., April 10, 2025 — In 2025, the Inflation Reduction Act (IRA) introduced significant Medicare reforms designed to reduce financial burdens for patients, including a new cap on out-of-pocket (OOP) prescription drug […]
Excitement Builds for Tremfya Among US Gastroenterologists as the FDA Approves its Expansion into Crohn’s Disease, Suggesting the Brand May Impact Competitor Skyrizi’s Growth
Gastroenterologists are enthusiastic about Tremfya’s subcutaneous induction option in Crohn’s disease, a key potential brand differentiator, according to Spherix Global Insights. EXTON, PA., March 28, 2025 – The treatment landscape for Crohn’s disease continues to evolve with the recent FDA approval of Johnson and Johnson Innovative Medicine’s Tremfya (guselkumab). This significant milestone makes Tremfya the […]